Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease

Iris T. Chan, Jeffery L. Kutok, Ifor R. Williams, Sarah Cohen, Sandra Moore, Hirokazu Shigematsu, Timothy J. Ley, Koichi Akashi, Michelle M. Le Beau, D. Gary Gilliland

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Most patients with acute promyelocytic leukemia (APL) express PML-RARα, the fusion product of t(15;17)(q22;q11.2). Transgenic mice expressing PML-RARα develop APL with long latency, low penetrance, and acquired cytogenetic abnormalities. Based on observations that 4% to 10% of APL patients harbor oncogenic ras mutations, we coexpressed oncogenic K-ras from its endogenous promoter with PML-RARα to generate a short-latency, highly penetrant mouse model of APL. The APL disease was characterized by splenomegaly, leukocytosis, extramedullary hematopoiesis (EMH) in spleen and liver with an increased proportion of immature myeloperoxidase-expressing myeloid forms; transplantability to secondary recipients; and lack of cytogenetic abnormalities. Bone marrow cells showed enhanced self-renewal in vitro. This model establishes a role for oncogenic ras in leukemia pathogenesis and thus validates the oncogenic RAS signaling pathway as a potential target for therapeutic inhibition in leukemia patients. This mouse model should be useful for investigating signaling pathways that promote self-renewal in APL and for testing the in vivo efficacy of RAS signaling pathway inhibitors in conjunction with other targeted therapies such as ATRA (all trans retinoic acid) and arsenic trioxide.

Original languageEnglish
Pages (from-to)1708-1715
Number of pages8
JournalBlood
Volume108
Issue number5
DOIs
Publication statusPublished - Sep 1 2006
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Ports and harbors
Tretinoin
Chromosome Aberrations
Liver
Peroxidase
Bone
Leukemia
Fusion reactions
Cells
Extramedullary Hematopoiesis
Penetrance
Splenomegaly
Leukocytosis
Testing
Bone Marrow Cells
Transgenic Mice
Spleen
Mutation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Moore, S., Shigematsu, H., ... Gary Gilliland, D. (2006). Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease. Blood, 108(5), 1708-1715. https://doi.org/10.1182/blood-2006-04-015040

Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease. / Chan, Iris T.; Kutok, Jeffery L.; Williams, Ifor R.; Cohen, Sarah; Moore, Sandra; Shigematsu, Hirokazu; Ley, Timothy J.; Akashi, Koichi; Le Beau, Michelle M.; Gary Gilliland, D.

In: Blood, Vol. 108, No. 5, 01.09.2006, p. 1708-1715.

Research output: Contribution to journalArticle

Chan, IT, Kutok, JL, Williams, IR, Cohen, S, Moore, S, Shigematsu, H, Ley, TJ, Akashi, K, Le Beau, MM & Gary Gilliland, D 2006, 'Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease', Blood, vol. 108, no. 5, pp. 1708-1715. https://doi.org/10.1182/blood-2006-04-015040
Chan IT, Kutok JL, Williams IR, Cohen S, Moore S, Shigematsu H et al. Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease. Blood. 2006 Sep 1;108(5):1708-1715. https://doi.org/10.1182/blood-2006-04-015040
Chan, Iris T. ; Kutok, Jeffery L. ; Williams, Ifor R. ; Cohen, Sarah ; Moore, Sandra ; Shigematsu, Hirokazu ; Ley, Timothy J. ; Akashi, Koichi ; Le Beau, Michelle M. ; Gary Gilliland, D. / Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease. In: Blood. 2006 ; Vol. 108, No. 5. pp. 1708-1715.
@article{d00a9b06ad6340a5992c9fa6974706f1,
title = "Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease",
abstract = "Most patients with acute promyelocytic leukemia (APL) express PML-RARα, the fusion product of t(15;17)(q22;q11.2). Transgenic mice expressing PML-RARα develop APL with long latency, low penetrance, and acquired cytogenetic abnormalities. Based on observations that 4{\%} to 10{\%} of APL patients harbor oncogenic ras mutations, we coexpressed oncogenic K-ras from its endogenous promoter with PML-RARα to generate a short-latency, highly penetrant mouse model of APL. The APL disease was characterized by splenomegaly, leukocytosis, extramedullary hematopoiesis (EMH) in spleen and liver with an increased proportion of immature myeloperoxidase-expressing myeloid forms; transplantability to secondary recipients; and lack of cytogenetic abnormalities. Bone marrow cells showed enhanced self-renewal in vitro. This model establishes a role for oncogenic ras in leukemia pathogenesis and thus validates the oncogenic RAS signaling pathway as a potential target for therapeutic inhibition in leukemia patients. This mouse model should be useful for investigating signaling pathways that promote self-renewal in APL and for testing the in vivo efficacy of RAS signaling pathway inhibitors in conjunction with other targeted therapies such as ATRA (all trans retinoic acid) and arsenic trioxide.",
author = "Chan, {Iris T.} and Kutok, {Jeffery L.} and Williams, {Ifor R.} and Sarah Cohen and Sandra Moore and Hirokazu Shigematsu and Ley, {Timothy J.} and Koichi Akashi and {Le Beau}, {Michelle M.} and {Gary Gilliland}, D.",
year = "2006",
month = "9",
day = "1",
doi = "10.1182/blood-2006-04-015040",
language = "English",
volume = "108",
pages = "1708--1715",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Oncogenic K-ras cooperates with PML-RARα to induce an acute promyelocytic leukemia-like disease

AU - Chan, Iris T.

AU - Kutok, Jeffery L.

AU - Williams, Ifor R.

AU - Cohen, Sarah

AU - Moore, Sandra

AU - Shigematsu, Hirokazu

AU - Ley, Timothy J.

AU - Akashi, Koichi

AU - Le Beau, Michelle M.

AU - Gary Gilliland, D.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Most patients with acute promyelocytic leukemia (APL) express PML-RARα, the fusion product of t(15;17)(q22;q11.2). Transgenic mice expressing PML-RARα develop APL with long latency, low penetrance, and acquired cytogenetic abnormalities. Based on observations that 4% to 10% of APL patients harbor oncogenic ras mutations, we coexpressed oncogenic K-ras from its endogenous promoter with PML-RARα to generate a short-latency, highly penetrant mouse model of APL. The APL disease was characterized by splenomegaly, leukocytosis, extramedullary hematopoiesis (EMH) in spleen and liver with an increased proportion of immature myeloperoxidase-expressing myeloid forms; transplantability to secondary recipients; and lack of cytogenetic abnormalities. Bone marrow cells showed enhanced self-renewal in vitro. This model establishes a role for oncogenic ras in leukemia pathogenesis and thus validates the oncogenic RAS signaling pathway as a potential target for therapeutic inhibition in leukemia patients. This mouse model should be useful for investigating signaling pathways that promote self-renewal in APL and for testing the in vivo efficacy of RAS signaling pathway inhibitors in conjunction with other targeted therapies such as ATRA (all trans retinoic acid) and arsenic trioxide.

AB - Most patients with acute promyelocytic leukemia (APL) express PML-RARα, the fusion product of t(15;17)(q22;q11.2). Transgenic mice expressing PML-RARα develop APL with long latency, low penetrance, and acquired cytogenetic abnormalities. Based on observations that 4% to 10% of APL patients harbor oncogenic ras mutations, we coexpressed oncogenic K-ras from its endogenous promoter with PML-RARα to generate a short-latency, highly penetrant mouse model of APL. The APL disease was characterized by splenomegaly, leukocytosis, extramedullary hematopoiesis (EMH) in spleen and liver with an increased proportion of immature myeloperoxidase-expressing myeloid forms; transplantability to secondary recipients; and lack of cytogenetic abnormalities. Bone marrow cells showed enhanced self-renewal in vitro. This model establishes a role for oncogenic ras in leukemia pathogenesis and thus validates the oncogenic RAS signaling pathway as a potential target for therapeutic inhibition in leukemia patients. This mouse model should be useful for investigating signaling pathways that promote self-renewal in APL and for testing the in vivo efficacy of RAS signaling pathway inhibitors in conjunction with other targeted therapies such as ATRA (all trans retinoic acid) and arsenic trioxide.

UR - http://www.scopus.com/inward/record.url?scp=33748177343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748177343&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-04-015040

DO - 10.1182/blood-2006-04-015040

M3 - Article

C2 - 16675706

AN - SCOPUS:33748177343

VL - 108

SP - 1708

EP - 1715

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -